• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺结节 AFIRMA GEC 检测的长期结果及文献复习:机构经验。

Long-Term Outcomes of Thyroid Nodule AFIRMA GEC Testing and Literature Review: An Institutional Experience.

机构信息

Department of Internal Medicine, Division of Endocrinology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA.

Department of Surgery, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA.

出版信息

Otolaryngol Head Neck Surg. 2020 May;162(5):634-640. doi: 10.1177/0194599820911718. Epub 2020 Mar 17.

DOI:10.1177/0194599820911718
PMID:32182188
Abstract

OBJECTIVE

To assess outcomes of thyroid nodules analyzed with the AFIRMA gene expression classifier (GEC) and to perform a comprehensive literature review.

STUDY DESIGN

Retrospective analysis of patients with thyroid nodules who underwent AFIRMA GEC testing at our institution.

SETTINGS

A tertiary care academic institution.

SUBJECTS AND METHODS

We collected clinical outcomes for 416 thyroid nodules that were analyzed with AFIRMA GEC between 2011 and 2015, including long-term follow-up through 2019. We performed a comprehensive literature review.

RESULTS

The resection rate for nodules with "suspicious" GEC results was 85% with a positive predictive value of 37%. The resection rate for nodules with "benign" GEC results was 24% with a negative predictive value of 90%. The prevalence of thyroid malignancy in patients with thyroid nodules with indeterminate cytology at our institution during this timeframe was 41%, thus lowering our negative predictive value. Mean follow-up duration for unresected nodules was 27.8 months. Our resection rates for nodules with "benign" GEC were among the highest reported in the literature.

CONCLUSIONS

Molecular marker testing of thyroid nodules with indeterminate cytology can aid in the surgical decision making by obviating the need for diagnostic surgery and/or guiding extent of resection. Patients with other indications for surgery may not benefit from such costly testing.

摘要

目的

评估使用 AFIRMA 基因表达分类器 (GEC) 分析的甲状腺结节的结果,并进行全面的文献复习。

研究设计

对在我们机构进行 AFIRMA GEC 检测的甲状腺结节患者进行回顾性分析。

设置

一家三级保健学术机构。

受试者和方法

我们收集了 2011 年至 2015 年间使用 AFIRMA GEC 分析的 416 个甲状腺结节的临床结果,包括截至 2019 年的长期随访。我们进行了全面的文献复习。

结果

“可疑”GEC 结果的结节切除率为 85%,阳性预测值为 37%。“良性”GEC 结果的结节切除率为 24%,阴性预测值为 90%。在此期间,我们机构具有不确定细胞学的甲状腺结节患者的甲状腺恶性肿瘤患病率为 41%,从而降低了我们的阴性预测值。未切除结节的平均随访时间为 27.8 个月。我们对“良性”GEC 结节的切除率在文献中报道的最高之列。

结论

对具有不确定细胞学的甲状腺结节进行分子标志物检测可以通过避免诊断性手术和/或指导切除范围来辅助手术决策。对于有其他手术指征的患者,这种昂贵的检测可能无益。

相似文献

1
Long-Term Outcomes of Thyroid Nodule AFIRMA GEC Testing and Literature Review: An Institutional Experience.甲状腺结节 AFIRMA GEC 检测的长期结果及文献复习:机构经验。
Otolaryngol Head Neck Surg. 2020 May;162(5):634-640. doi: 10.1177/0194599820911718. Epub 2020 Mar 17.
2
Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.单中心经验应用 Afirma 和 Thyroseq 检测在甲状腺结节不明确病例。
Thyroid. 2021 Sep;31(9):1376-1382. doi: 10.1089/thy.2020.0801. Epub 2021 Apr 29.
3
Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.在不确定甲状腺结节中,Affirma 基因测序分类器与基因表达分类器的比较。
Thyroid. 2019 Aug;29(8):1115-1124. doi: 10.1089/thy.2018.0733. Epub 2019 Jul 17.
4
An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.一项关于基因表达分类器(Afirma)在评估细胞学不确定的甲状腺结节中的独立研究。
J Clin Endocrinol Metab. 2014 Nov;99(11):4069-77. doi: 10.1210/jc.2013-3584. Epub 2014 Apr 29.
5
Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.甲状腺结节细胞诊断中异型性的限定词与不同的Afirma基因表达分类器结果及临床结局相关。
Cancer Cytopathol. 2017 May;125(5):313-322. doi: 10.1002/cncy.21827. Epub 2017 Feb 2.
6
Multicenter clinical experience with the Afirma gene expression classifier.多中心临床应用 Afirma 基因表达分类器的经验。
J Clin Endocrinol Metab. 2014 Jan;99(1):119-25. doi: 10.1210/jc.2013-2482. Epub 2013 Dec 20.
7
Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.甲状腺结节不明原因的分子检测:Afirma 基因表达分类器和 ThyroSeq 面板的性能。
Cancer Cytopathol. 2018 Jul;126(7):471-480. doi: 10.1002/cncy.21993. Epub 2018 Apr 10.
8
The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.具有乳头样核特征的非侵袭性滤泡性甲状腺肿瘤对Afirma基因表达分类器性能的影响。
Cancer Cytopathol. 2017 Sep;125(9):683-691. doi: 10.1002/cncy.21879. Epub 2017 May 24.
9
Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.对细胞学不确定的甲状腺结节的 Afirma 基因组测序分类器和基因表达分类器的独立比较。
Thyroid. 2019 May;29(5):650-656. doi: 10.1089/thy.2018.0726. Epub 2019 Mar 22.
10
Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.在细胞学不确定的甲状腺结节中,Afirma 基因测序分类器与基因表达分类器的性能比较。
J Am Soc Cytopathol. 2022 Mar-Apr;11(2):74-78. doi: 10.1016/j.jasc.2021.07.002. Epub 2021 Jul 22.

引用本文的文献

1
Diagnostic accuracy of Afirma gene expression classifier, Afirma gene sequencing classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis.Afirma基因表达分类器、Afirma基因测序分类器、ThyroSeq v2和ThyroSeq v3对不确定(贝塞斯达III级和IV级)甲状腺结节的诊断准确性:一项荟萃分析。
Endocr Connect. 2024 Jun 13;13(7). doi: 10.1530/EC-24-0170. Print 2024 Jul 1.
2
Assessing Bias and Limitations of Clinical Validation Studies of Molecular Diagnostic Tests for Indeterminate Thyroid Nodules: Systematic Review and Meta-Analysis.评估用于不确定甲状腺结节的分子诊断检测的临床验证研究的偏倚和局限性:系统评价和荟萃分析。
Thyroid. 2022 Oct;32(10):1144-1157. doi: 10.1089/thy.2022.0269. Epub 2022 Sep 26.
3
Long-term Follow-up of Cytologically Indeterminate Thyroid Nodules Found Benign on Molecular Testing: A Validation Study.分子检测显示为良性的细胞学检查结果不确定的甲状腺结节的长期随访:一项验证研究
OTO Open. 2022 Mar 18;6(1):2473974X221083542. doi: 10.1177/2473974X221083542. eCollection 2022 Jan-Mar.
4
Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?超声模式和临床参数是否能为细胞学不确定的结节中分子检测预测的甲状腺癌概率提供信息?
Thyroid. 2021 Nov;31(11):1673-1682. doi: 10.1089/thy.2021.0119. Epub 2021 Sep 1.
5
Molecular Testing for Thyroid Nodules Including Its Interpretation and Use in Clinical Practice.甲状腺结节的分子检测:包括其解读及在临床实践中的应用。
Ann Surg Oncol. 2021 Dec;28(13):8884-8891. doi: 10.1245/s10434-021-10307-4. Epub 2021 Jul 18.
6
Thyroid Nodule Molecular Testing: Is It Ready for Prime Time?甲状腺结节分子检测:是否已准备好投入使用?
Front Endocrinol (Lausanne). 2020 Oct 9;11:590128. doi: 10.3389/fendo.2020.590128. eCollection 2020.